Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 7/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8788878 | 0.80 | CLK1 (0.58) | MAPKAPK2KDRROCK2MKNK1ROCK1 | |
| SCHEMBL26715276 | 0.79 | MAPKAPK2 (0.71) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL6530324 | 0.79 | MKNK1 (0.58) | MAPKAPK2KDRROCK2MKNK1ROCK1 | |
| SCHEMBL20783989 | 0.79 | MAPKAPK2 (1.00) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL30611438 | 0.79 | MKNK1 (0.58) | MAPKAPK2KDRROCK2MKNK1ROCK1 | |
| SCHEMBL3459554 | 0.79 | MAPKAPK2 (0.71) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL22749728 | 0.77 | KDR (0.65) | MAPKAPK2KDRROCK2MKNK1ROCK1 | |
| SCHEMBL26717703 | 0.76 | MAPKAPK2 (0.67) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL6606097 | 0.76 | MAPKAPK2 (0.67) | MAPKAPK2KDRROCK2ROCK1IGF1R | |
| SCHEMBL2772522 | 0.76 | ROCK2 (0.62) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076464-A1 | CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | INSERM OMSTOTIT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE (FR) | 2019-03-14 | — | — | US | disclosed |
| EP-3429597-A1 | CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017158050-A1 | CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-09-21 | — | — | WO | disclosed |
| US-8455471-B2 | Compositions of CHK1 inhibitors and cyclodextrin | ICOS CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | WISDOM WENDY A | 2010-01-28 | — | — | US | disclosed |
| EP-2063879-A2 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | ICOS Corporation (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008067027-A2 | COMPOSITIONS OF CHKL INHIBITORS AND CYCLODEXTRIN | ICOS CORPORATION (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | CHEK1, CHEK2, DDB1 | MAPKAPK2 1162/4885KDR 3949/4885ROCK2 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.